American Century Companies
VTGN icon

American Century Companies’s VistaGen Therapeutics VTGN Stock Holding History

American Century Companies’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-48,770
Closed -$32.3K – 2932
2025
Q4 		$32.3K Buy
48,770
+7,698
+19% +$27.8K ﹤0.01% 2803
2025
Q3 		$146K Buy
41,072
+10,009
+32% +$29.9K ﹤0.01% 2722
2025
Q2 		$62.1K Hold
31,063
– – ﹤0.01% 2819
2025
Q1 		$77.7K Buy
31,063
+1,061
+4% +$3K ﹤0.01% 2843
2024
Q4 		$88.5K Sell
30,002
-195
-0.6% -$549 ﹤0.01% 2847
2024
Q3 		$90.9K Sell
30,197
-118
-0.4% -$403 ﹤0.01% 2841
2024
Q2 		$105K Buy
30,315
+9,984
+49% +$43.2K ﹤0.01% 2810
2024
Q1 		$107K Buy
+20,331
New +$97.8K ﹤0.01% 2854

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies's VTGN Position: Q1 2026 in Review

American Century Companies sold out of VistaGen Therapeutics (VTGN) in Q1 2026, closing a stake of 48,770 shares — an estimated $32.3K sold.

American Century Companies first reported a position in VTGN in Q1 2024 and held it in 8 quarters. The position peaked at $146K in Q3 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • American Century Companies reported no remaining VistaGen Therapeutics position as of Q1 2026 after selling out during the quarter.
  • American Century Companies sold 48,770 VistaGen Therapeutics shares in Q1 2026, an estimated $32.3K.
  • American Century Companies first reported a position in VistaGen Therapeutics in Q1 2024 and held it in 8 quarters.
  • American Century Companies's VistaGen Therapeutics position peaked at $146K in Q3 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on American Century Companies's 13F filing for Q1 2026, filed 15 May 2026.